Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

Given high uncertainty around the economic outlook, authorities should stand ready to adjust monetary policy as needed, the Washington-based IMF said in a statement dated February 20. It said ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around ...

Inward direct investment climbed $1.75 trillion, or 4.4 percent, reaching a record $41 trillion, according to the IMF’s latest Coordinated Direct Investment Survey, which provides detailed information ...

The Board of Governors, the highest decision-making body of the IMF, consists of one governor and one alternate governor for each member country. The governor is appointed by the member country and is ...

PRESIDENT Donald Trump warned drugmakers in a private meeting that tariffs are coming and said companies should hustle to move overseas manufacturing to the US, according to two people familiar with ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Pakistan had been engaged with the International Monetary Fund (IMF) for acquiring the climate fund and expected $1-1.5 billion support from the global lender, Federal Finance Minister Muhammad ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other expensive stocks. We previously covered the 10 cheapest stocks insiders are buying recently.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...